Brief: Initial Results From Phase 2 Trial Demonstrate Potential Of Trilaciclib

G1 Therapeutics

02/11/2022 11:37

Nov 2 (Reuters) - G1 Therapeutics Inc  GTHX.O :
    * INITIAL RESULTS FROM PHASE 2 TRIAL DEMONSTRATE POTENTIAL
OF
TRILACICLIB TO REDUCE ADVERSE EVENTS RELATED TO AN ANTIBODY DRUG
CONJUGATE (ADC)
    * G1 THERAPEUTICS INC- INITIAL DATA HIGHLIGHT POTENTIAL FOR
TRILACICLIB TO MEANINGFULLY REDUCE ADVERSE EVENTS RELATED TO USE
OF SACITUZUMAB
    * G1 THERAPEUTICS INC - TRILACICLIB IS WELL TOLERATED WHEN
ADMINISTERED PRIOR TO SACITUZUMAB

Source text for Eikon:  ID:nGNX7Ph8g0 
Further company coverage:  GTHX.O 
 ((Reuters.Briefs@thomsonreuters.com;))